Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10676751 | 0.84 | NOTUM (0.36) | TNFCYP11B1CYP11B2 | |
| SCHEMBL3502260 | 0.83 | GRN (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL6104782 | 0.81 | ACSS2 (0.34) | — | |
| SCHEMBL10916866 | 0.81 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL10456979 | 0.80 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL877589 | 0.80 | KDM4E (0.43) | — | |
| SCHEMBL9408078 | 0.80 | ALDH1A1 (0.36) | TNFCYP11B1CYP11B2 | |
| SCHEMBL3503135 | 0.79 | BRS3 (0.35) | — | |
| SCHEMBL3502442 | 0.78 | — | — | |
| SCHEMBL3501940 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-0194984-B1 | DERIVATIVES OF IMIDAZOLE, THEIR PREPARATION AND UTILISATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES | CONTINENTAL PHARMA, INC. (BE) | 1990-04-04 | — | — | EP | disclosed |
| US-4738979-A | ADRENERGIC RECEPTORS; ANTI-CONVULSIVE DRUG; TREATMENT OF METABOLIC AND NEUTRAL DISORDERS | G. D. SEARLE & CO. (US) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | TNF 4170/4885CYP11B1 34/4885CYP11B2 32/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | TNF 4098/4885CYP11B1 25/4885CYP11B2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.